Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Trading Down 5.6% – Time to Sell?

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI)’s stock price traded down 5.6% during mid-day trading on Friday . The stock traded as low as $0.2802 and last traded at $0.2830. 316,567 shares were traded during trading, a decline of 23% from the average session volume of 409,831 shares. The stock had previously closed at $0.2997.

Calidi Biotherapeutics Stock Down 5.6%

The stock has a fifty day moving average price of $0.78 and a 200-day moving average price of $1.23. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.11.

Institutional Investors Weigh In On Calidi Biotherapeutics

Several hedge funds have recently bought and sold shares of CLDI. Virtu Financial LLC acquired a new stake in Calidi Biotherapeutics during the 4th quarter worth about $25,000. DRW Securities LLC acquired a new position in shares of Calidi Biotherapeutics in the 4th quarter valued at about $173,000. Geode Capital Management LLC increased its holdings in shares of Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after purchasing an additional 12,334 shares during the period. Finally, Warberg Asset Management LLC purchased a new stake in shares of Calidi Biotherapeutics in the third quarter worth approximately $28,000. 12.53% of the stock is owned by hedge funds and other institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.